Verve Therapeutics Inc (NASDAQ:VERV) has a beta value of -5.55% and has seen 4.94 shares traded in the last trading session. The company, currently valued at $985.92M, closed the last trade at $11.12 per share which meant it lost -$2.67 on the day or 11.06% during that session. The VERV stock price is -2.52% off its 52-week high price of $11.40 and 74.28% above the 52-week low of $2.86. If we look at the company’s 10-day average daily trading volume, we find that it stood at 12.31 million shares traded. The 3-month trading volume is 1.53 shares.
The consensus among analysts is that Verve Therapeutics Inc (VERV) is Buy stock at the moment, with a recommendation rating of 84.74. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Sporting 11.06% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the VERV stock price touched $11.12 or saw a rise of 2.46%. Year-to-date, Verve Therapeutics Inc shares have moved 109.87%, while the 5-day performance has seen it change 75.00%. Over the past 30 days, the shares of Verve Therapeutics Inc (NASDAQ:VERV) have changed 139.91%. Short interest in the company has seen 19.84 million shares shorted with days to cover at 6.99.
Wall Street analysts have a consensus price target for the stock at $15, which means that the shares’ value could jump 25.87% from current levels. The projected low price target is $15.0 while the price target rests at a high of $15.0. In that case, then, we find that the current price level is -34.89% off the targeted high while a plunge would see the stock gain -34.89% from current levels.
Verve Therapeutics Inc (VERV) estimates and forecasts
The company’s shares have gained 104.44% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.84% -42.43% over the past 5 years. Earnings growth for 2025 is a modest -3.29% while over the next 5 years, the company’s earnings are expected to decrease by -0.31%.
VERV Dividends
Verve Therapeutics Inc is expected to release its next earnings report on 2025-May-14 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
Insiders own 5.10% of the company shares, while shares held by institutions stand at 94.63% with a share float percentage of 99.72%. Investors are also buoyed by the number of investors in a company, with Verve Therapeutics Inc having a total of 277.0 institutions that hold shares in the company. The top two institutional holders are ALPHABET INC. with over 12.35 million shares worth more than $60.26 million. As of 2024-06-30, ALPHABET INC. held 14.6618% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 6.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $32.31 million and represent 7.8598% of shares outstanding.
